Outpatient administration of naxitamab in combination with granulocyte‐macrophage colony‐stimulating factor in patients with refractory and/or relapsed high‐risk neuroblastoma: Management of adverse events

BACKGROUND: Naxitamab is a humanized GD2‐binding monoclonal antibody that received accelerated approval from the U.S. Food and Drug Administration for refractory or relapsed high‐risk neuroblastoma limited to bone or bone marrow. Trial 201 (NCT03363373) is an ongoing global clinical trial to evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Mora, Jaume, Chan, Godfrey C., Morgenstern, Daniel A., Nysom, Karsten, Bear, Melissa K., Tornøe, Karen, Kushner, Brian H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875606/
https://www.ncbi.nlm.nih.gov/pubmed/35579862
http://dx.doi.org/10.1002/cnr2.1627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875606/
https://www.ncbi.nlm.nih.gov/pubmed/35579862
http://dx.doi.org/10.1002/cnr2.1627

Ejemplares similares